JP2013095730A - Film coating composition and oral solid preparation - Google Patents

Film coating composition and oral solid preparation Download PDF

Info

Publication number
JP2013095730A
JP2013095730A JP2011242053A JP2011242053A JP2013095730A JP 2013095730 A JP2013095730 A JP 2013095730A JP 2011242053 A JP2011242053 A JP 2011242053A JP 2011242053 A JP2011242053 A JP 2011242053A JP 2013095730 A JP2013095730 A JP 2013095730A
Authority
JP
Japan
Prior art keywords
coating composition
film coating
oral solid
solid preparation
mass
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011242053A
Other languages
Japanese (ja)
Other versions
JP5608626B2 (en
Inventor
Takuya Yokozawa
拓也 横澤
Yuichi Nishiyama
裕一 西山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shin Etsu Chemical Co Ltd
Original Assignee
Shin Etsu Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shin Etsu Chemical Co Ltd filed Critical Shin Etsu Chemical Co Ltd
Priority to JP2011242053A priority Critical patent/JP5608626B2/en
Priority to KR1020120123360A priority patent/KR102011512B1/en
Publication of JP2013095730A publication Critical patent/JP2013095730A/en
Application granted granted Critical
Publication of JP5608626B2 publication Critical patent/JP5608626B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09DCOATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D101/00Coating compositions based on cellulose, modified cellulose, or cellulose derivatives
    • C09D101/08Cellulose derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/08Cellulose derivatives
    • C08L1/26Cellulose ethers
    • C08L1/28Alkyl ethers
    • C08L1/284Alkyl ethers with hydroxylated hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L29/00Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal or ketal radical; Compositions of hydrolysed polymers of esters of unsaturated alcohols with saturated carboxylic acids; Compositions of derivatives of such polymers
    • C08L29/02Homopolymers or copolymers of unsaturated alcohols
    • C08L29/04Polyvinyl alcohol; Partially hydrolysed homopolymers or copolymers of esters of unsaturated alcohols with saturated carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09DCOATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D5/00Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects produced; Filling pastes
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09DCOATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D7/00Features of coating compositions, not provided for in group C09D5/00; Processes for incorporating ingredients in coating compositions
    • C09D7/40Additives
    • C09D7/60Additives non-macromolecular
    • C09D7/61Additives non-macromolecular inorganic
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09DCOATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D7/00Features of coating compositions, not provided for in group C09D5/00; Processes for incorporating ingredients in coating compositions
    • C09D7/40Additives
    • C09D7/65Additives macromolecular
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2301/00Characterised by the use of cellulose, modified cellulose or cellulose derivatives
    • C08J2301/08Cellulose derivatives
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2401/00Characterised by the use of cellulose, modified cellulose or cellulose derivatives
    • C08J2401/08Cellulose derivatives
    • C08J2401/26Cellulose ethers
    • C08J2401/28Alkyl ethers
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2429/00Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal, or ketal radical; Hydrolysed polymers of esters of unsaturated alcohols with saturated carboxylic acids; Derivatives of such polymer
    • C08J2429/02Homopolymers or copolymers of unsaturated alcohols
    • C08J2429/04Polyvinyl alcohol; Partially hydrolysed homopolymers or copolymers of esters of unsaturated alcohols with saturated carboxylic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Materials Engineering (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

PROBLEM TO BE SOLVED: To provide a film coating composition which has excellent texture in the oral cavity and also has improved leachability, and to provide an oral solid preparation imparted with high luster by being coated using the film coating composition.SOLUTION: The film coating composition at least comprises: a base including methylcellulose alone or hydroxypropyl cellulose and/or polyvinyl alcohol in addition to methylcellulose in 100 pts.mass; a plasticizer in 18 to 150 pts.mass; and talc in 40 to 500 pts.mass. Further, the oral solid preparation at least comprises: a core part at least including a medicine; and the film coating composition coating the core part. Further, a method for producing an oral solid preparation at least including: a step of coating a solution in which the film coating composition is dissolved or dispersed into a solvent; and the subsequent drying step is provided.

Description

本発明は、フィルムコーティング組成物及びこれを用いた経口固形製剤に関する。   The present invention relates to a film coating composition and an oral solid preparation using the same.

フィルムコーティングや糖衣は、経口固形製剤における、薬物の不快な味に対するマスキング、薬物の安定性を保つための遮光、経口固形製剤の識別性を向上させるための着色コーティング、経口固形製剤の搬送過程における摩損の防止あるいは製品としての美観の向上などの目的で広く行われている。   Film coating and sugar coating are used to mask the unpleasant taste of drugs in oral solid preparations, light-shielding to maintain drug stability, colored coatings to improve the discrimination of oral solid preparations, and in the process of transporting oral solid preparations Widely used for the purpose of preventing wear and improving the aesthetics of products.

特に錠剤の美観に関しては糖衣コーティングを施すことにより高い光沢が得られることが知られている。錠剤に高い光沢性を付与する試みとしては、ヒドロキシプロピルメチルセルロースにポリエチレングリコールとタルクを特定の比率で配合した組成物を用いることで錠剤表面に高い光沢性を付与できることが提案されている(特許文献1)。また、苦味のマスキング方法としては、メチルセルロースのゲル化特性を応用してメチルセルロースを用いてフィルムコーティングすることにより、口腔内では崩壊しないフィルムコーティングが提案されている(特許文献2)。更に、メチルセルロースに糖類又は糖アルコールを配合することで、苦味マスキングに優れ、薬物の溶出性を改善する方法が提案されている(特許文献3)。   In particular, regarding the aesthetics of tablets, it is known that high gloss can be obtained by applying a sugar coating. As an attempt to impart high gloss to a tablet, it has been proposed that high gloss can be imparted to the tablet surface by using a composition in which polyethylene glycol and talc are blended in a specific ratio with hydroxypropylmethylcellulose (Patent Literature). 1). Moreover, as a bitterness masking method, a film coating that does not disintegrate in the oral cavity has been proposed by applying the gelation characteristics of methylcellulose and film coating using methylcellulose (Patent Document 2). Furthermore, a method has been proposed in which saccharides or sugar alcohols are blended with methylcellulose, which is excellent in bitterness masking and improves drug elution (Patent Document 3).

特開2008−201713号公報JP 2008-201713 A 特開昭60−13719号公報JP 60-13719 A 特開2001−151672号公報JP 2001-151672 A

しかしながら、糖衣コーティングは糖衣の作業工程に長時間を要し、製造コストの上昇や、製剤が服用困難な程大きくなること、コーティングに用いられるゼラチンの主成分であるタンパク質が変性してしまい安定性に欠けるという問題がある。また、特許文献1のフィルムコーティング組成物では高い光沢を持つ錠剤が得られるものの、ヒドロキシプロピルメチルセルロースを用いてコーティングをした経口固形製剤は口中で速やかに溶解し、口腔内でべとつき感や、ぬめり感があるため高齢者や乳児者などの患者によっては服用しづらいと言った問題があった。これは、ヒドロキシプロピルメチルセルロースの熱ゲル化温度が高く、口腔内で熱ゲル化を起こさないために、フィルムが速やかに溶解することに起因する。一方で、特許文献2で挙げられているようにメチルセルロースを用いる場合、メチルセルロースが37℃で熱ゲル化を起こして溶解できないために、べとつき感やぬめり感を感じずに服用することが可能であるが、熱ゲル化が原因となり、薬物の溶出が遅れることが懸念される。そのため、特許文献3では、メチルセルロースに糖類又は糖アルコールを配合することで溶出性が改善されることが提案されているが、この方法による溶出性の改善は十分ではなく、また、糖類等を配合することで透湿性が向上してしまい、錠剤の保存時の安定性を確保できないと言った問題があった。   However, the sugar coating requires a long time for the sugar coating process, increases the manufacturing cost, becomes so large that the preparation is difficult to take, and the protein that is the main component of gelatin used for coating is denatured and stable. There is a problem of lacking. In addition, although the film coating composition of Patent Document 1 can produce tablets with high gloss, oral solid preparations coated with hydroxypropylmethylcellulose dissolve quickly in the mouth, and feel sticky and slimy in the mouth. There was a problem that it was difficult to take depending on patients such as elderly people and infants. This is because hydroxypropylmethylcellulose has a high thermal gelation temperature and does not cause thermal gelation in the oral cavity, so that the film dissolves quickly. On the other hand, when methylcellulose is used as described in Patent Document 2, methylcellulose cannot be dissolved due to thermal gelation at 37 ° C., so it can be taken without feeling sticky or slimy. However, there is a concern that the dissolution of the drug may be delayed due to thermal gelation. Therefore, in Patent Document 3, it is proposed that the elution is improved by adding saccharide or sugar alcohol to methylcellulose, but the improvement of the elution by this method is not sufficient, and saccharide or the like is added. As a result, moisture permeability was improved, and there was a problem that stability during storage of tablets could not be ensured.

本発明は、従来のフィルムコーティングと比べて、口腔内での食感に優れ、かつ溶出性が改善されたフィルムコーティング組成物及びかかるフィルムコーティング組成物を用いてコーティングすることで高い光沢が付与された経口固形製剤を提供することを目的とする。   The present invention provides a film coating composition that has an excellent mouthfeel and improved elution properties compared to conventional film coatings, and high gloss is imparted by coating with such film coating compositions. An object of the present invention is to provide an oral solid preparation.

本発明者らは、上記課題を解決するために鋭意検討を重ねた結果、メチルセルロースに可塑剤とタルクを特定の比率で配合することで上記目的が達成されることを見出し、本発明を完成した。
本発明によれば、メチルセルロース単独又はメチルセルロースに加えてヒドロキシプロピルセルロース及び/又はポリビニルアルコールを有する基剤100質量部と、18〜150質量部の可塑剤と、40〜500質量部のタルクを少なくとも含んでなるフィルムコーティング組成物が提供される。また、薬物を少なくとも含有する芯部と、該芯部を被覆する上記フィルムコーティング組成物を少なくとも含む経口固形製剤が提供される。さらに、薬物を少なくとも含有する芯部に、上記フィルムコーティング組成物を溶媒に溶解もしくは分散した溶液を塗布する工程と、その後の乾燥工程とを少なくとも含む経口固形製剤の製造方法が提供される。
As a result of intensive studies to solve the above problems, the present inventors have found that the above object can be achieved by blending a plasticizer and talc at a specific ratio in methylcellulose, and completed the present invention. .
According to the present invention, methylcellulose alone or in addition to methylcellulose, 100 parts by mass of a base having hydroxypropylcellulose and / or polyvinyl alcohol, 18-150 parts by mass of plasticizer, and 40-500 parts by mass of talc are included at least. A film coating composition is provided. Also provided is an oral solid preparation comprising at least a core containing a drug and at least the film coating composition covering the core. Furthermore, a method for producing an oral solid preparation comprising at least a step of applying a solution obtained by dissolving or dispersing the film coating composition in a solvent to a core containing at least a drug and a subsequent drying step is provided.

本発明のフィルムコーティング組成物を用いて経口固形製剤をコーティングすれば、従来のフィルムコーティングに比べて口腔内でのべとつき感、ぬめり感が改善され、口腔内での食感に優れ、スムーズな嚥下が図れ、且つ、速やかに活性成分を溶出できる溶出性が改善された経口固形製剤を提供できる。また、本発明によれば、糖衣コーティングをすることなく高い光沢性が付与された経口固形製剤を提供できる。   If an oral solid preparation is coated using the film coating composition of the present invention, the stickiness and sliminess in the oral cavity are improved compared to conventional film coating, the mouthfeel is excellent, and smooth swallowing Therefore, it is possible to provide an oral solid preparation with improved dissolution that can quickly dissolve the active ingredient. Moreover, according to this invention, the oral solid formulation to which high glossiness was provided without carrying out sugar coating can be provided.

実施例1〜8及び比較例1の溶出試験の結果を示す。The result of the elution test of Examples 1-8 and Comparative Example 1 is shown.

本発明のフィルムコーティング用組成物は、メチルセルロース単独又はメチルセルロースに加えてヒドロキシプロピルセルロース及び/又はポリビニルアルコールを有する基剤、可塑剤及びタルクを少なくとも含有する。
メチルセルロース(以下、「MC」とも記載する)の粘度は、コーティングを実施するために高濃度溶液としてスプレーできるよう低いものが好ましい。具体的には、20℃における2質量%水溶液の粘度が、好ましくは2〜50mPa・s、更に好ましくは2〜25mPa・s、特に好ましくは2〜15mPa・sである。2mPa・s未満では、MC重合度が極端に低下するためフィルムとしての強度を保持できないおそれがある。また、50mPa・sを超えると、コーティング水溶液の濃度を低く抑えなければならず実用的ではないおそれがある。なお、上記粘度は第16改正日本薬局方に記載の粘度測定方法で測定できる。
MCのメトキシ基の置換度は、特に制限されないが、好ましくは26.0〜33.0質量%、更に好ましくは27.5〜31.5質量%である。なお、MCの置換度は、第16改正日本薬局方に記載のメチルセルロース及びヒドロキシプロピルメチルセルロース、ヒドロキシプロピルセルロースの置換度の測定方法に準拠した方法で測定できる。
The film coating composition of the present invention contains at least a base having a hydroxypropyl cellulose and / or polyvinyl alcohol, a plasticizer and talc in addition to methyl cellulose alone or methyl cellulose.
The viscosity of methylcellulose (hereinafter also referred to as “MC”) is preferably low so that it can be sprayed as a highly concentrated solution to perform coating. Specifically, the viscosity of a 2% by mass aqueous solution at 20 ° C. is preferably 2 to 50 mPa · s, more preferably 2 to 25 mPa · s, and particularly preferably 2 to 15 mPa · s. If it is less than 2 mPa · s, the degree of polymerization of MC is extremely lowered, so that the strength as a film may not be maintained. On the other hand, if it exceeds 50 mPa · s, the concentration of the aqueous coating solution must be kept low, which may be impractical. In addition, the said viscosity can be measured with the viscosity measuring method as described in the 16th revision Japanese Pharmacopoeia.
Although the substitution degree of the methoxy group of MC is not particularly limited, it is preferably 26.0 to 33.0% by mass, more preferably 27.5 to 31.5% by mass. The degree of substitution of MC can be measured by a method based on the method for measuring the degree of substitution of methylcellulose, hydroxypropylmethylcellulose, and hydroxypropylcellulose described in the 16th revised Japanese Pharmacopoeia.

MC単独の基剤の他に、MCにヒドロキシプロピルセルロース(以下、「HPC」とも記載する)やポリビニルアルコール(以下、「PVA」とも記載する)を配合した基剤を用いることもできる。
HPCの粘度は、コーティングを実施するために低い方が好ましい。具体的には、20℃における2質量%水溶液の粘度が、好ましくは2〜50mPa・s、更に好ましくは3〜10mPa・s、特に好ましくは6〜10mPa・sである。2mPa・s未満では、MC重合度が極端に低下するためフィルムとしての強度を保持できないおそれがある。また、50mPa・sを超えると、コーティング水溶液の濃度を低く抑えなければならず実用的ではないおそれがある。なお、MCと同様の測定方法で測定できる。
また、ヒドロキシプロポキシ基の置換度は特に制限されないが、好ましくは53.4〜77.5質量%、更に好ましくは60.0〜70.0質量%である。なお、HPCの置換度は、MCと同様の測定方法で測定できる。
HPCの配合量は、特に制限されないが、MCの溶出性を改善するという観点から、MCとHPCの質量比で好ましくは49:51〜10:90、更に好ましくは45:55〜35:65である。HPCの配合量が少ないと溶出性の改善に劣り、他方HPCの配合量が多いと経口固形製剤を服用した際に口腔内でぬめり感、べとつき感を感じる恐れがある。
Other MC sole base, MC hydroxypropyl cellulose (hereinafter also referred to as "HPC") and polyvinyl alcohol (hereinafter, also referred to as "PVA") may be used base compounded with.
The viscosity of the HPC is preferably lower in order to carry out the coating. Specifically, the viscosity of a 2 mass% aqueous solution at 20 ° C is preferably 2 to 50 mPa · s, more preferably 3 to 10 mPa · s, and particularly preferably 6 to 10 mPa · s. If it is less than 2 mPa · s, the degree of polymerization of MC is extremely lowered, so that the strength as a film may not be maintained. On the other hand, if it exceeds 50 mPa · s, the concentration of the aqueous coating solution must be kept low, which may be impractical. It can be measured by the same measurement method as MC.
Further, the degree of substitution of the hydroxypropoxy group is not particularly limited, but is preferably 53.4-77.5% by mass, more preferably 60.0-70.0% by mass. In addition, the substitution degree of HPC can be measured by the same measurement method as MC.
The blending amount of HPC is not particularly limited, but from the viewpoint of improving the dissolution property of MC, the mass ratio of MC to HPC is preferably 49:51 to 10:90, more preferably 45:55 to 35:65. is there. When the amount of HPC is small, the dissolution property is inferior. On the other hand, when the amount of HPC is large, there is a risk of feeling slimy and sticky in the oral cavity when taking an oral solid preparation.

PVAは、医薬品添加物規格で規定されたポリビニルアルコール(完全けん化物)およびポリビニルアルコール(部分けん化物)が好ましい。完全けん化ポリビニルアルコールは、けん化度が97モル%以上であり、部分けん化ポリビニルアルコールは、好ましくは、けん化度が78〜96モル%である。
PVAの平均重合度は、好ましくは200〜3500、更に好ましくは400〜1000である。PVAの平均重合度は、JIS K6726に記載の平均重合度の測定方法で測定できる。
PVAの配合量は、特に制限されないが、MCとの相溶性の観点から、MCとPVAの質量比で好ましくは90:10から10:90、更に好ましくは50:50から15:85、特に好ましくは40:60から20:80の範囲である。PVAの配合量が上記の好ましい範囲より少ないと溶出性の改善に劣る場合があり、PVAの配合量が上記の好ましい範囲より多いと経口固形製剤を服用した際に口腔内でぬめり感、べとつき感を感じる場合がある。
PVA is preferably polyvinyl alcohol (completely saponified product) or polyvinyl alcohol (partially saponified product) specified by the pharmaceutical additive standards. The fully saponified polyvinyl alcohol has a saponification degree of 97 mol% or more, and the partially saponified polyvinyl alcohol preferably has a saponification degree of 78 to 96 mol%.
The average degree of polymerization of PVA is preferably 200-3500, more preferably 400-1000. The average degree of polymerization of PVA can be measured by the method for measuring the average degree of polymerization described in JIS K6726.
The amount of PVA is not particularly limited, but from the viewpoint of compatibility with MC, the mass ratio of MC to PVA is preferably 90:10 to 10:90, more preferably 50:50 to 15:85, and particularly preferably Is in the range of 40:60 to 20:80. When the amount of PVA is less than the above preferred range, the dissolution may be inferior, and when the amount of PVA is more than the above preferred range, when the oral solid preparation is taken, the mouth feels sticky and sticky. You may feel

本発明でいられる可塑剤としては、ポリエチレングリコール、グリセリン、プロピレングリコール、トリアセチン、クエン酸トリエチルなどが挙げられるが、MCとの相溶性に優れ、高い光沢性を付与するという観点から、特にポリエチレングリコールが好適である。
ポリエチレングリコールの重量平均分子量は、特に制限されないが、高い光沢を付与するという観点から、好ましくは200〜35000であり、更に好ましくは1500〜35000である。ポリエチレングリコールの重量平均分子量は、ゲル・パーミエーション・クロマトグラフィー(GPC)を用いたポリスチレン換算で得られる。
フィルムコーティング組成物中の可塑剤の含有量は、基剤100質量部に対して、18〜150質量部であるが、好ましくは22〜100質量部、更に好ましくは40〜80質量部である。可塑剤の含有量が18質量部より少ないと錠剤の光沢性が劣り、可塑剤を必要以上多く配合しても、経済性が劣る。なお、基剤は、MC単独の基剤、MCとHPCからなる基剤、MCとPVAからなる基剤、及びMCとHPCとPVAからなる基剤から選択できる。
Examples of the plasticizer that can be used in the present invention include polyethylene glycol, glycerin, propylene glycol, triacetin, triethyl citrate, and the like. From the viewpoint of excellent compatibility with MC and imparting high gloss, polyethylene glycol is particularly preferable. Is preferred.
The weight average molecular weight of polyethylene glycol is not particularly limited, but is preferably 200 to 35000, and more preferably 1500 to 35000, from the viewpoint of imparting high gloss. The weight average molecular weight of polyethylene glycol is obtained in terms of polystyrene using gel permeation chromatography (GPC).
Although content of the plasticizer in a film coating composition is 18-150 mass parts with respect to 100 mass parts of bases, Preferably it is 22-100 mass parts, More preferably, it is 40-80 mass parts. When the content of the plasticizer is less than 18 parts by mass, the gloss of the tablet is inferior, and even if the plasticizer is added more than necessary, the economy is inferior. The base can be selected from a base consisting of MC alone, a base consisting of MC and HPC, a base consisting of MC and PVA, and a base consisting of MC, HPC and PVA.

フィルムコーティング用組成物中のタルクの含有量は、基剤100質量部に対して、40〜500質量部、好ましくは80〜380質量部、より好ましくは150〜250質量部である。タルクの含有量が少ないと錠剤の光沢性が劣り、他方タルクを必要以上多く配合しても、経済性が劣る。
本発明のフィルムコーティング組成物は、可塑剤とタルクとを上記の割合で含有することにより、被覆量の少ないエッジ部分においてコーティング被膜の崩壊が促進され、通常37℃では溶解しないMCのコーティングフィルムから薬物の溶出が起こると考えられる。
The content of talc in the composition for film coating is 40 to 500 parts by mass, preferably 80 to 380 parts by mass, and more preferably 150 to 250 parts by mass with respect to 100 parts by mass of the base. If the content of talc is low, the gloss of the tablet is inferior. On the other hand, even if more talc is added than necessary, the economy is inferior.
Since the film coating composition of the present invention contains the plasticizer and talc in the above ratio, the coating film disintegration is promoted at the edge portion where the coating amount is small, and the MC coating film that does not normally dissolve at 37 ° C. It is thought that drug elution occurs.

コーティング組成物は、必要に応じて、通常製剤学的に認められる薬物、組成物の分散性を良くする界面活性剤、着色剤、顔料、甘味料、コーティング剤、消泡剤等を加えても良い。   If necessary, the coating composition may be added with drugs that are generally recognized pharmaceutically, surfactants that improve the dispersibility of the composition, colorants, pigments, sweeteners, coating agents, antifoaming agents, and the like. good.

経口固形製剤は、薬物を少なくとも含有する芯部と、芯部を被覆するフィルムコーティング組成物を少なくとも含む。
薬物は、経口投与可能な薬物であれば特に限定されるものではない。
The oral solid preparation includes at least a core containing a drug and at least a film coating composition for covering the core.
The drug is not particularly limited as long as it can be administered orally.

薬物を少なくとも含有する芯部には、賦形剤、結合剤、崩壊剤、滑択剤、凝集防止剤、医薬化合物の溶解補助剤等、通常この分野で常用され得る種々の添加剤を配合してもよい。賦形剤としては、白糖、乳糖、マンニトール、グルコース等の糖類、でんぷん、結晶セルロース、リン酸カルシウム、硫酸カルシウム等が挙げられ、結合剤としては、ポリビニルアルコール、ポリアクリル酸、ポリメタクリル酸、ポリビニルピロリドン、グルコース、白糖、乳糖、麦芽糖、デキストリン、ソルビトール、マンニトール、ヒドロキシエチルセルロース、ヒドロキシプロピルメチルセルロース、ヒドロキシプロピルセルロース、マクロゴール類、アラビアゴム、ゼラチン、寒天、でんぷん等が挙げられる。崩壊剤としては、低置換度ヒドロキシプロピルセルロース、カルメロース又はその塩、クロスカルメロースナトリウム、カルボキシメチルスターチナトリウム、クロスポリビニルピロリドン、結晶セルロース及び結晶セルロース・カルメロースナトリウム等が挙げられる。また、滑択剤、凝集防止剤としては、タルク、ステアリン酸マグネシウム、ステアリン酸カルシウム、コロイダルシリカ、ステアリン酸、ワックス類、硬化油、ポリエチレングリコール類、安息香酸ナトリウム等が挙げられる。更に、医薬化合物の溶解補助剤としては、フマル酸、コハク酸、リンゴ酸、アジピン酸等の有機酸等が挙げられる。これら添加剤の含有量は、薬剤の種類等に応じて適宜決定することができる。   In the core containing at least the drug, various additives that can be commonly used in this field, such as excipients, binders, disintegrants, lubricants, anti-aggregation agents, and solubilizing agents for pharmaceutical compounds, are blended. May be. Examples of the excipient include sugars such as sucrose, lactose, mannitol, glucose, starch, crystalline cellulose, calcium phosphate, calcium sulfate and the like, and binders include polyvinyl alcohol, polyacrylic acid, polymethacrylic acid, polyvinylpyrrolidone, Examples include glucose, sucrose, lactose, maltose, dextrin, sorbitol, mannitol, hydroxyethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, macrogol, gum arabic, gelatin, agar, starch, and the like. Examples of the disintegrant include low-substituted hydroxypropyl cellulose, carmellose or a salt thereof, croscarmellose sodium, sodium carboxymethyl starch, cros polyvinylpyrrolidone, crystalline cellulose, crystalline cellulose / carmellose sodium, and the like. Further, examples of the lubricant and the aggregation inhibitor include talc, magnesium stearate, calcium stearate, colloidal silica, stearic acid, waxes, hardened oil, polyethylene glycols, sodium benzoate and the like. Furthermore, examples of solubilizing agents for pharmaceutical compounds include organic acids such as fumaric acid, succinic acid, malic acid, and adipic acid. The content of these additives can be appropriately determined according to the type of the drug.

本発明のフィルムコーティング組成物によりコーティングされる経口固形製剤としては、錠剤、顆粒剤、細粒剤、カプセル剤等が挙げられるが、その中でも特に錠剤が好ましい。   Examples of the oral solid preparation coated with the film coating composition of the present invention include tablets, granules, fine granules, capsules, etc. Among them, tablets are particularly preferable.

次に、経口固形製剤の製造方法について説明する。
コーティングの装置は、従来公知の手段を用いることができる。一般的に行われているのはスプレーコーティングであるが、その場合は、パンコーティング装置、ドラムタイプコーティング装置、流動層コーティング装置、撹拌流動コーティング装置を用いて行えばよく、これらの装置に付帯するスプレー装置にはエアースプレー、エアレススプレー、3流体スプレー等いずれをも用いることができる。
Next, the manufacturing method of an oral solid formulation is demonstrated.
Conventionally known means can be used for the coating apparatus. Although spray coating is generally performed, in that case, it may be performed using a pan coating apparatus, a drum type coating apparatus, a fluidized bed coating apparatus, and a stirring fluidized coating apparatus. As the spray device, any of air spray, airless spray, three-fluid spray, and the like can be used.

本発明のフィルムコーティング組成物溶液を塗布する方法として、例えば上述したコーティング装置を用い、薬物を含有する芯部に、MC、可塑剤及びタルクにさらに必要に応じて添加剤を添加したフィルムコーティング組成物を水またはエタノール等の有機溶媒あるいはこれらの混合液に溶解もしくは分散させた溶液を調整し、噴霧等により塗布することが挙げられる。
MC、HPC、PVA、可塑剤のポリエチレングリコールは、水溶性であり、水とエタノール等の有機溶剤の混合液にも溶解する。タルクは、無機粉末であり、水や有機溶媒に溶解せず、分散される。分散を考慮するとタルクの平均粒径は、レーザ回折散乱法を用いて、好ましくは0.1〜20μmの範囲である。
As a method for applying the film coating composition solution of the present invention, for example, using the above-described coating apparatus, a film coating composition in which MC, a plasticizer, and talc are further added with additives as necessary to the core containing the drug. A solution prepared by dissolving or dispersing the product in water or an organic solvent such as ethanol or a mixture thereof may be prepared and applied by spraying or the like.
MC, HPC, PVA, and the plasticizer polyethylene glycol are water-soluble and dissolve in a mixed solution of water and an organic solvent such as ethanol. Talc is an inorganic powder and is not dissolved in water or an organic solvent but is dispersed. In consideration of dispersion, the average particle diameter of talc is preferably in the range of 0.1 to 20 μm using a laser diffraction scattering method.

その後、同コーティング装置内で、又は同コーティング装置から取り出して、加熱等により乾燥を行い、経口固形製剤を製造することができる。
乾燥は、特に制限されないが、高い光沢を付与するという点において、乾燥とともにポリッシングを行うことが好ましく、好ましくは、乾燥時に経口固形製剤同士がこすれあう状態(ポリッシング)とする。乾燥は、例えば、上述したコーティング装置内にて、好ましくは20〜100℃、更に好ましくは30〜80℃の温度で行う。コーティング装置内を回転又は撹拌することにより、乾燥とともにポリッシングを行うことができる。また、乾燥は、ポリッシングの有無にかかわらず、好ましくは10分以上、更に好ましくは20分〜60分、特に好ましくは20分〜40分行うことが好ましい。60分以上乾燥又は乾燥しながらポリッシングを行っても光沢度に変化はなく経済性が劣る。
Then, it can take out in the coating apparatus or from the coating apparatus, and can be dried by heating or the like to produce an oral solid preparation.
Drying is not particularly limited, but in terms of imparting high gloss, it is preferable to perform polishing together with drying, and preferably a state in which oral solid preparations are rubbed with each other during drying (polishing). Drying is preferably performed at a temperature of 20 to 100 ° C., more preferably 30 to 80 ° C. in the above-described coating apparatus. By rotating or stirring the inside of the coating apparatus, polishing can be performed together with drying. The drying is preferably performed for 10 minutes or more, more preferably 20 minutes to 60 minutes, and particularly preferably 20 minutes to 40 minutes, regardless of the presence or absence of polishing. Even if polishing is performed while drying or drying for 60 minutes or more, the glossiness does not change and the economy is inferior.

芯部(素錠)の表面にコーティングされるフィルムコーティング組成物の被覆量は、固形性製剤の種類、形、大きさ、表面状態、更に固形製剤中に含まれる薬剤及び添加剤の性質等によって異なるが、例えば、素錠に対して、好ましくは1〜10質量%、更に好ましくは1〜7質量%、特に好ましくは2〜6質量%である。被覆量が少なすぎると、完全な皮膜が得られず、他方多すぎるとコーティングに要する時間が必要となる場合がある。   The coating amount of the film coating composition coated on the surface of the core (uncoated tablet) depends on the type, shape, size, surface state of the solid preparation, and the properties of the drug and additives contained in the solid preparation. Although different, for example, it is preferably 1 to 10% by mass, more preferably 1 to 7% by mass, and particularly preferably 2 to 6% by mass with respect to the uncoated tablet. If the coating amount is too small, a complete film cannot be obtained. On the other hand, if the coating amount is too large, the time required for coating may be required.

本発明の経口固形製剤は、フィルムコーティング組成物からなるフィルム層の下にヒドロキシプロピルメチルセルロースなどの通常この分野で常用され得る種々のコーティング基剤を用いてアンダーコーティングを行い、複数のフィルムを形成させた多層フィルムコーティング経口固形製剤としても良い。   The oral solid preparation of the present invention forms a plurality of films by undercoating with various coating bases that can be commonly used in this field such as hydroxypropylmethylcellulose under the film layer comprising the film coating composition. A multilayer film-coated oral solid preparation may also be used.

このようにして製造された経口固形製剤は、第16改正日本薬局方に記載の溶出試験(37℃、パドル法、50回転/分、溶媒900mLの水)において85%以上の薬物を放出するまでの時間が、好ましくは試験開始から10分以内である。また、該経口固形製剤表面の光沢度が、精密光沢計(GM−26D(20°/60°)型、村上色彩技術研究所製)を用いて60度鏡面光沢度を測定(錠剤ホルダー5mmφ、測定面積:約3×3mm)した際に、好ましくは6.0以上である。更に、該経口固形製剤は服用した際に口腔内でぬめり感やべとつき感を感じることがなく服用可能である。   Until the oral solid preparation thus produced releases 85% or more of the drug in the dissolution test described in the 16th revised Japanese Pharmacopoeia (37 ° C., paddle method, 50 rotations / min, solvent 900 mL water) Is preferably within 10 minutes from the start of the test. Further, the glossiness of the surface of the oral solid preparation was determined by measuring a 60-degree specular gloss using a precision gloss meter (GM-26D (20 ° / 60 °) type, manufactured by Murakami Color Research Laboratory) (tablet holder 5 mmφ, (Measurement area: about 3 × 3 mm), it is preferably 6.0 or more. Furthermore, the oral solid preparation can be taken without feeling slimy or sticky in the oral cavity when taken.

以下、本発明について実施例をあげて具体的に説明するが、本発明はこれらに限定されるものではない。
実施例1
リボフラビン(東京田辺製薬社製)2質量部、乳糖(フロイント産業社製、ダイラクトースS)90質量部、低置換度ヒドロキシプロピルセルロース(ヒドロキシプロピル基置換度11質量%)8質量部、ステアリン酸マグネシウム0.5質量部を粉体混合し、ロータリー打錠機(菊水製作所製Vergo)にて、直径8mm、打錠圧1t、打錠予圧0.3t、回転数20rpm、一錠あたりの重量が200mgとなるように打錠し、リボフラビンを薬物に含有した素錠を作成した。
次に、MC(メトキシ基置換度28質量%、20℃における2質量%水溶液の粘度が4.0mPa・s)13.5g、ポリエチレングリコール(日本油脂社製、マクロゴール6000)8.1g(MCに対して0.60)、タルク(クラウン社製)27.0g(MCに対して2.0)、酸化チタン(石原産業製)5.4gを、精製水396.0gに溶解・分散しコーティング溶液を調製した。
上記コーティング溶液を用い下記条件にて、素錠100質量部に対して固形分質量で5質量部までコーティングを行った。コーティング終了後、コーティング装置内にて給気温度60℃、パン回転数24rpmで30分間乾燥・ポリッシングを行い、目的のコーティング錠剤を得た。
使用したコーティング条件は以下の通りである。
装置:通気式パンコーター(内径33cm)
仕込み量:1kg
吸気温度:80℃
排気温度:47〜50℃
吸気エアー量:1m/min
パン回転数:18〜24rpm
スプレー速度:6g/min
スプレーエアー圧:150kPa
EXAMPLES Hereinafter, although an Example is given and this invention is demonstrated concretely, this invention is not limited to these.
Example 1
2 parts by mass of riboflavin (manufactured by Tanabe Seiyaku Co., Ltd.), 90 parts by mass of lactose (manufactured by Freund Sangyo Co., Ltd., Dilactose S), 8 parts by mass of low-substituted hydroxypropylcellulose (hydroxypropyl group substitution degree 11% by mass), magnesium stearate 0.5 parts by mass are mixed with powder, and a rotary tableting machine (Vergo, manufactured by Kikusui Seisakusho) is 8 mm in diameter, tableting pressure 1 t, tableting preload 0.3 t, rotation speed 20 rpm, and weight per tablet is 200 mg. Tableting was carried out so that an uncoated tablet containing riboflavin in the drug was prepared.
Next, MC (28% by mass of methoxy group substitution, viscosity of 2% by mass aqueous solution at 20 ° C. is 4.0 mPa · s) 13.5 g, polyethylene glycol (manufactured by NOF Corporation, Macrogol 6000) 8.1 g (MC 0.60), talc (manufactured by Crown) 27.0 g (2.0 to MC), and titanium oxide (manufactured by Ishihara Sangyo) 5.4 g were dissolved and dispersed in 396.0 g of purified water and coated A solution was prepared.
Using the above coating solution, coating was performed up to 5 parts by mass with a solid content based on 100 parts by mass of the uncoated tablet. After the coating was completed, drying and polishing were performed for 30 minutes in a coating apparatus at an air supply temperature of 60 ° C. and a pan rotation speed of 24 rpm, to obtain a target coated tablet.
The coating conditions used are as follows.
Equipment: Ventilated pan coater (inner diameter 33cm)
Charge amount: 1kg
Intake air temperature: 80 ℃
Exhaust temperature: 47-50 ° C
Intake air volume: 1m 3 / min
Pan rotation speed: 18-24rpm
Spray speed: 6g / min
Spray air pressure: 150kPa

実施例2
実施例1のコーティング溶液の作成で、MCを24.75g、ポリエチレングリコールを5.45g(MCに対して0.22)、タルクを19.80g(MCに対して0.8)、酸化チタンを9.90g、精製水を490.11gに変えてコーティング溶液を作成し、実施例1と同様にしてコーティング錠剤を得た。
Example 2
In the preparation of the coating solution of Example 1, 24.75 g of MC, 5.45 g of polyethylene glycol (0.22 with respect to MC), 19.80 g of talc (0.8 with respect to MC), and titanium oxide A coating solution was prepared by changing 9.90 g and purified water to 490.11 g, and a coated tablet was obtained in the same manner as in Example 1.

実施例3
実施例1のコーティング溶液の作成で、MCを10.5g、ポリエチレングリコールを2.31g(MCに対して0.22)、タルクを39.9g(MCに対して3.8)、酸化チタンを4.2g、精製水を293.09gに変えてコーティング溶液を作成し、実施例1と同様にしてコーティング錠剤を得た。
Example 3
In the preparation of the coating solution of Example 1, 10.5 g of MC, 2.31 g of polyethylene glycol (0.22 with respect to MC), 39.9 g of talc (3.8 with respect to MC), and titanium oxide A coating solution was prepared by changing 4.2 g and purified water to 293.09 g, and a coated tablet was obtained in the same manner as in Example 1.

実施例4
実施例1のコーティング溶液の作成で、MCを18.0g、ポリエチレングリコールを22.5g(MCに対して1.25)、タルクを14.4g(MCに対して0.8)、酸化チタンを7.2g、精製水を537.9gに変えてコーティング溶液を作成し、実施例1と同様にしてコーティング錠剤を得た。
Example 4
In the preparation of the coating solution of Example 1, 18.0 g of MC, 22.5 g of polyethylene glycol (1.25 with respect to MC), 14.4 g of talc (0.8 with respect to MC), and titanium oxide A coating solution was prepared by changing 7.2 g and purified water to 537.9 g, and a coated tablet was obtained in the same manner as in Example 1.

実施例5
実施例1のコーティング溶液の作成で、MCを10.5g、ポリエチレングリコールを13.13g(MCに対して1.25)、タルクを39.9g(MCに対して3.8)、酸化チタンを4.2g、精製水を282.28gに変えてコーティング溶液を作成し、実施例1と同様にしてコーティング錠剤を得た。
Example 5
In the preparation of the coating solution of Example 1, 10.5 g of MC, 13.13 g of polyethylene glycol (1.25 for MC), 39.9 g of talc (3.8 for MC), and titanium oxide A coating solution was prepared by changing 4.2 g and purified water to 282.28 g, and a coated tablet was obtained in the same manner as in Example 1.

実施例6
実施例1のコーティング溶液の作成で、MCを16g、ポリエチレングリコールを2.88g(MCに対して0.18)、タルクを32g(MCに対して2.0)、酸化チタンを6.4g、精製水を342.72gに変えてコーティング溶液を作成し、実施例1と同様にしてコーティング錠剤を得た。
Example 6
In the preparation of the coating solution of Example 1, 16 g of MC, 2.88 g of polyethylene glycol (0.18 with respect to MC), 32 g of talc (2.0 with respect to MC), 6.4 g of titanium oxide, Purified water was changed to 342.72 g to prepare a coating solution, and coated tablets were obtained in the same manner as in Example 1.

実施例7
実施例1のコーティング溶液の作成で、MCを25g、ポリエチレングリコールを15g(MCに対して0.60)、タルクを12.5g(MCに対して0.5)、酸化チタンを10g、精製水を437.5gに変えてコーティング溶液を作成し、実施例1と同様にしてコーティング錠剤を得た。
Example 7
In the preparation of the coating solution of Example 1, 25 g of MC, 15 g of polyethylene glycol (0.60 with respect to MC), 12.5 g of talc (0.5 with respect to MC), 10 g of titanium oxide, and purified water Was changed to 437.5 g to prepare a coating solution, and coated tablets were obtained in the same manner as in Example 1.

実施例8
実施例1のコーティング溶液の作成で、MCを6.4g、更にHPC(日本曹達社製、ヒドロキシプロポキシ基置換度63質量%、20℃における2質量%水溶液の粘度が8.0mPa・s)9.6g(MC:HPC=4:6)を加えて、ポリエチレングリコールを9.6g(MC/HPCに対して0.60)、タルクを32.0g(MC/HPCに対して2.0)、酸化チタンを6.4g、精製水を336.0gに変えて、コーティング溶液を作成し、実施例1と同様にしてコーティング錠剤を得た。
Example 8
In the preparation of the coating solution of Example 1, 6.4 g of MC and HPC (manufactured by Nippon Soda Co., Ltd., hydroxypropoxy group substitution degree 63 mass%, viscosity of 2 mass% aqueous solution at 20 ° C. is 8.0 mPa · s) 9 .6 g (MC: HPC = 4: 6), polyethylene glycol 9.6 g (0.60 for MC / HPC), talc 32.0 g (2.0 for MC / HPC), A coating solution was prepared by changing 6.4 g of titanium oxide and 336.0 g of purified water, and a coated tablet was obtained in the same manner as in Example 1.

実施例9
実施例1のコーティング溶液の作成で、MCを4.8g、更にPVA(日本酢ビ・ポバール社製、重合度500、けん化度88モル%)11.2g(MC:PVA=3:7)を加えて、ポリエチレングリコールを9.6g(MC/PVAに対して0.60)、タルクを32.0g(MC/PVAに対して2.0)、酸化チタンを6.4g、精製水を336.0gに変えて、コーティング溶液を作成し、実施例1と同様にしてコーティング錠剤を得た。
Example 9
In the preparation of the coating solution of Example 1, 4.8 g of MC, and further 11.2 g (MC: PVA = 3: 7) of PVA (manufactured by Nippon Acetate / Poval, polymerization degree 500, saponification degree 88 mol%). In addition, 9.6 g of polyethylene glycol (0.60 with respect to MC / PVA), 32.0 g of talc (2.0 with respect to MC / PVA), 6.4 g of titanium oxide, and 336. of purified water. The coating solution was changed to 0 g, and a coated tablet was obtained in the same manner as in Example 1.

比較例1
実施例1のコーティング溶液の作成でポリエチレングリコール、タルク及び酸化チタンは入れずに、MC56.0gを精製水744.0gに変えてコーティング溶液を作成し、実施例1と同様にしてコーティング錠剤を得た。
Comparative Example 1
In the preparation of the coating solution of Example 1, without adding polyethylene glycol, talc and titanium oxide, MC56.0 g was changed to purified water 744.0 g to prepare a coating solution, and a coated tablet was obtained in the same manner as in Example 1. It was.

比較例2
実施例1のコーティング溶液の作成で、ポリエチレングリコールは入れずに、MCを14g、タルクを53.2g(MCに対して3.8)、酸化チタンを5.6g、精製水を277.2gに変えてコーティング溶液を作成し、実施例1と同様にしてコーティング錠剤を得た。
Comparative Example 2
In the preparation of the coating solution of Example 1, 14 g of MC, 53.2 g of talc (3.8 to MC), 5.6 g of titanium oxide, and 277.2 g of purified water without adding polyethylene glycol. A coating solution was prepared by changing, and coated tablets were obtained in the same manner as in Example 1.

比較例3
実施例1のコーティング溶液の作成で、タルクは入れずにMCを22.5g、ポリエチレングリコールを28.13g(MCに対して1.25)、酸化チタンを9g、精製水を390.32gに変えてコーティング溶液を作成し、実施例1と同様にしてコーティング錠剤を得た。
Comparative Example 3
In the preparation of the coating solution of Example 1, 22.5 g of MC without talc, 28.13 g of polyethylene glycol (1.25 with respect to MC), 9 g of titanium oxide, and 390.32 g of purified water were changed. A coating solution was prepared and coated tablets were obtained in the same manner as in Example 1.

比較例4
実施例1のコーティング溶液の作成で、MCを16g、ポリエチレングリコールを2.4g(MCに対して0.15)、タルクを32g(MCに対して2.0)、酸化チタンを6.4g、精製水を343.2gに変えてコーティング溶液を作成し、実施例1と同様にしてコーティング錠剤を得た。
Comparative Example 4
In the preparation of the coating solution of Example 1, 16 g of MC, 2.4 g of polyethylene glycol (0.15 with respect to MC), 32 g of talc (2.0 with respect to MC), 6.4 g of titanium oxide, Purified water was changed to 343.2 g to prepare a coating solution, and coated tablets were obtained in the same manner as in Example 1.

比較例5
実施例1のコーティング溶液の作成で、MCを25g、ポリエチレングリコールを15g(MCに対して0.60)、タルクを7.5g(MCに対して0.3)、酸化チタンを10g、精製水を442.5gに変えてコーティング溶液を作成し、実施例1と同様にしてコーティング錠剤を得た。
Comparative Example 5
In preparation of the coating solution of Example 1, 25 g of MC, 15 g of polyethylene glycol (0.60 with respect to MC), 7.5 g of talc (0.3 with respect to MC), 10 g of titanium oxide, and purified water Was changed to 442.5 g to prepare a coating solution, and coated tablets were obtained in the same manner as in Example 1.

比較例6
実施例1のコーティング溶液の作成で、MCをヒドロキシプロピルメチルセルロース(メトキシ基置換度28%、ヒドロキシプロポキシ基置換度9%)に変えてヒドロキシプロピルメチルセルロースを16.0g、ポリエチレングリコールを9.6g、タルクを32.0g、酸化チタンを6.4g、精製水を336.0gに変えてコーティング溶液を作成し、実施例1と同様にしてコーティング錠剤を得た。
Comparative Example 6
In the preparation of the coating solution of Example 1, MC was changed to hydroxypropylmethylcellulose (methoxy group substitution degree 28%, hydroxypropoxy group substitution degree 9%), hydroxypropylmethylcellulose 16.0 g, polyethylene glycol 9.6 g, talc Was changed to 32.0 g, titanium oxide 6.4 g, and purified water 334.0 g to prepare a coating solution. In the same manner as in Example 1, a coated tablet was obtained.

<コーティング錠剤の溶出特性の評価>
実施例1〜9及び比較例1〜6で得られたコーティング錠剤の溶出試験を第16改正日本薬局方記載の溶出試験(37℃、パドル法、50回転/分、溶媒900mLの水)により評価を行った。実施例1〜9及び比較例1の溶出挙動を図1に示す。
溶出試験のサンプリングは、溶出試験開始後1分、3分、5分、7分、10分、20分、30分後に行い、薬物の85%以上が溶出した時間を溶出時間として求め、表1に示す。
図1及び表1から明らかなように、本発明のコーティング錠剤は比較例1のコーティング錠剤に比べ溶出性が改善されている。
<Evaluation of dissolution characteristics of coated tablets>
The dissolution test of the coated tablets obtained in Examples 1 to 9 and Comparative Examples 1 to 6 was evaluated by the dissolution test described in the 16th revised Japanese Pharmacopoeia (37 ° C., paddle method, 50 rotations / minute, solvent 900 mL water). Went. The elution behaviors of Examples 1 to 9 and Comparative Example 1 are shown in FIG.
Sampling of the dissolution test was performed 1 minute, 3 minutes, 5 minutes, 7 minutes, 10 minutes, 20 minutes, and 30 minutes after the start of the dissolution test, and the time at which 85% or more of the drug was dissolved was determined as the dissolution time. Shown in
As is apparent from FIG. 1 and Table 1, the coated tablet of the present invention has improved dissolution compared to the coated tablet of Comparative Example 1.

<コーティング錠剤の光沢度の評価>
実施例1〜9及び比較例1〜6で得られたコーティング錠剤の光沢度を精密光沢計(GM−26D(20°/60°)型、村上色彩技術研究所製)を用いて60度鏡面光沢度を測定(錠剤ホルダー5mmφ、測定面積:約3×3mm)した結果を表1に示す。
表1から明らかなように、本発明のコーティング錠剤は比較例の1〜5のコーティング錠剤に比べて高い光沢度を示した。
<Evaluation of glossiness of coated tablets>
The glossiness of the coated tablets obtained in Examples 1 to 9 and Comparative Examples 1 to 6 was measured using a precision gloss meter (GM-26D (20 ° / 60 °) type, manufactured by Murakami Color Research Laboratory) with a mirror surface of 60 °. Table 1 shows the results of measuring the glossiness (tablet holder 5 mmφ, measurement area: about 3 × 3 mm).
As is apparent from Table 1, the coated tablet of the present invention showed higher glossiness than the coated tablets of Comparative Examples 1 to 5.

<口腔内でのぬめり感の有無の評価>
実施例1〜9及び比較例1〜6で得られたコーティング錠剤を健康な成人6人に投与して、口腔内でぬめり感を感じた人の数を表1にまとめた。
表1から明らかなように、本発明のコーティング錠剤は口腔内でぬめり感を示さなかったのに対して、比較例6のコーティング錠剤はぬめり感を示した。
<Evaluation of the presence or absence of sliminess in the oral cavity>
The coated tablets obtained in Examples 1 to 9 and Comparative Examples 1 to 6 were administered to 6 healthy adults, and the number of people who felt slimy in the oral cavity was summarized in Table 1.
As is clear from Table 1, the coated tablet of the present invention did not show a slimy feeling in the oral cavity, whereas the coated tablet of Comparative Example 6 showed a slimy feeling.

Figure 2013095730
Figure 2013095730

Claims (5)

メチルセルロース単独又はメチルセルロースに加えてヒドロキシプロピルセルロース及び/又はポリビニルアルコールを有する基剤100質量部と、18〜150質量部の可塑剤と、40〜500質量部のタルクを少なくとも含んでなるフィルムコーティング組成物。   A film coating composition comprising at least 100 parts by weight of a base having hydroxypropylcellulose and / or polyvinyl alcohol in addition to methylcellulose alone or methylcellulose, 18 to 150 parts by weight of a plasticizer, and 40 to 500 parts by weight of talc. . 上記可塑剤が、ポリエチレングリコールである請求項1に記載のフィルムコーティング組成物。   The film coating composition according to claim 1, wherein the plasticizer is polyethylene glycol. 薬物を少なくとも含有する芯部と、該芯部を被覆する請求項1又は請求項2に記載のフィルムコーティング組成物を少なくとも含む経口固形製剤。   3. An oral solid preparation comprising at least a core containing a drug and at least the film coating composition according to claim 1 which covers the core. 薬物を少なくとも含有する芯部に、請求項1又は2に記載のフィルムコーティング組成物を溶媒に溶解もしくは分散した溶液を塗布する工程と、その後の乾燥工程とを少なくとも含む経口固形製剤の製造方法。   A method for producing an oral solid preparation comprising at least a step of applying a solution obtained by dissolving or dispersing the film coating composition of claim 1 or 2 in a solvent to a core containing at least a drug, and a subsequent drying step. 上記乾燥工程が、塗布後の経口固形製剤を乾燥しながらポリッシングを行うことを含み、10分以上行われる請求項4に記載の経口固形製剤の製造方法。   The method for producing an oral solid preparation according to claim 4, wherein the drying step includes polishing while drying the oral solid preparation after application, and is performed for 10 minutes or more.
JP2011242053A 2011-11-04 2011-11-04 Film coating composition and oral solid preparation Active JP5608626B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2011242053A JP5608626B2 (en) 2011-11-04 2011-11-04 Film coating composition and oral solid preparation
KR1020120123360A KR102011512B1 (en) 2011-11-04 2012-11-02 Film coating composition and oral solid preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011242053A JP5608626B2 (en) 2011-11-04 2011-11-04 Film coating composition and oral solid preparation

Publications (2)

Publication Number Publication Date
JP2013095730A true JP2013095730A (en) 2013-05-20
JP5608626B2 JP5608626B2 (en) 2014-10-15

Family

ID=48618053

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011242053A Active JP5608626B2 (en) 2011-11-04 2011-11-04 Film coating composition and oral solid preparation

Country Status (2)

Country Link
JP (1) JP5608626B2 (en)
KR (1) KR102011512B1 (en)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4832644B1 (en) * 1970-08-20 1973-10-08
JPS6013719A (en) * 1983-07-01 1985-01-24 Shin Etsu Chem Co Ltd Coated solid rrug
JPH0959147A (en) * 1995-08-22 1997-03-04 Shin Etsu Chem Co Ltd Rapidly soluble coating agent composition and its production
JP2000044464A (en) * 1998-08-03 2000-02-15 Taisho Pharmaceut Co Ltd Film-coated tablet
JP2001139495A (en) * 1999-11-19 2001-05-22 Shin Etsu Chem Co Ltd Film-coating agent and oral solid preparation
JP2001151672A (en) * 1999-11-19 2001-06-05 Shin Etsu Chem Co Ltd Water-based film-coating agent and solid preparation for oral administration
JP2008201713A (en) * 2007-02-20 2008-09-04 Ss Pharmaceut Co Ltd Film coating composition
JP2012211101A (en) * 2011-03-31 2012-11-01 Ssp Co Ltd Film coating composition

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4832644B1 (en) * 1970-08-20 1973-10-08
JPS6013719A (en) * 1983-07-01 1985-01-24 Shin Etsu Chem Co Ltd Coated solid rrug
JPH0959147A (en) * 1995-08-22 1997-03-04 Shin Etsu Chem Co Ltd Rapidly soluble coating agent composition and its production
JP2000044464A (en) * 1998-08-03 2000-02-15 Taisho Pharmaceut Co Ltd Film-coated tablet
JP2001139495A (en) * 1999-11-19 2001-05-22 Shin Etsu Chem Co Ltd Film-coating agent and oral solid preparation
JP2001151672A (en) * 1999-11-19 2001-06-05 Shin Etsu Chem Co Ltd Water-based film-coating agent and solid preparation for oral administration
JP2008201713A (en) * 2007-02-20 2008-09-04 Ss Pharmaceut Co Ltd Film coating composition
JP2012211101A (en) * 2011-03-31 2012-11-01 Ssp Co Ltd Film coating composition

Also Published As

Publication number Publication date
KR102011512B1 (en) 2019-08-16
JP5608626B2 (en) 2014-10-15
KR20130049740A (en) 2013-05-14

Similar Documents

Publication Publication Date Title
JP4868695B2 (en) Oral preparation with good disintegration
JP5871886B2 (en) Easy-to-use solid preparation
JP5787882B2 (en) Enteric tablets
JP6521874B2 (en) Film-coated orally disintegrating tablets
CA2847614A1 (en) Easily dosable solid preparation
TWI697341B (en) Coated tablets and the production thereof
JP2023026417A (en) Enteric tablet containing dimethyl fumarate
JP5787881B2 (en) Enteric tablets
JP2013253030A (en) Film coating composition, oral solid preparation and method for producing the same
JP2021024865A (en) Abiraterone acetate-containing preparation
JP2001151672A (en) Water-based film-coating agent and solid preparation for oral administration
TW201735927A (en) Film-coating tablet wherein active ingredient has good chemical stability
JP5608626B2 (en) Film coating composition and oral solid preparation
JP6396220B2 (en) Film coating liquid, oral solid preparation and method for producing the same
JP2001139495A (en) Film-coating agent and oral solid preparation
JP2006256975A (en) Guaifenesin-containing preparation
JP2016056208A (en) Film coating composition, oral solid preparation and method for producing the same
JP2018109026A (en) Easily swallowable solid preparation
JP4059916B2 (en) Film coating method for solid dispersion
JP6673798B2 (en) Film-coated pharmaceutical preparation containing capecitabine as active ingredient
KR20070103709A (en) Method for coating solid dispersion with film
JP2024039317A (en) Composition for film coating, solid preparation, and method for producing solid preparation
JP2021104941A (en) Tablets with high drug content and manufacturing methods thereof
JP2024013563A (en) Composition for coating and solid preparation, and method for producing solid preparation
JP2008081512A (en) Method for film-coating solid dispersion

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131029

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140225

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140428

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140801

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140901

R150 Certificate of patent or registration of utility model

Ref document number: 5608626

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150